Zhejiang Medicine Co., Ltd. (SHA:600216)

Market Cap	13.21B
Revenue (ttm)	9.03B
Net Income (ttm)	977.95M
Shares Out	961.64M
EPS (ttm)	1.02
PE Ratio	13.43
Forward PE	11.55
Dividend	0.15 (1.12%)
Ex-Dividend Date	Jul 10, 2024

Volume	4,010,500
Average Volume	21,896,847
Open	13.72
Previous Close	13.42
Day's Range	13.52 - 13.72
52-Week Range	8.96 - 19.40
Beta	0.57
RSI	36.64
Earnings Date	Apr 24, 2025

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceutical products in China. The company products include synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company provides injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin products....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 6,227
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2023, Zhejiang Medicine's revenue was 7.79 billion, a decrease of -3.96% compared to the previous year's 8.12 billion. Earnings were 429.64 million, a decrease of -20.37%.